Display options
Cite
Yigit M, Değirmencioğlu S, Ugurlu E, et al. Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer. Mol Clin Oncol. 2017;6(5):708-712doi: 10.3892/mco.2017.1195.
Yigit, M., Değirmencioğlu, S., Ugurlu, E., & Yaren, A. (2017). Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer. Molecular and clinical oncology, 6(5), 708-712. https://doi.org/10.3892/mco.2017.1195
Yigit, Murat, et al. "Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer." Molecular and clinical oncology vol. 6,5 (2017): 708-712. doi: https://doi.org/10.3892/mco.2017.1195
Yigit M, Değirmencioğlu S, Ugurlu E, Yaren A. Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer. Mol Clin Oncol. 2017 May;6(5):708-712. doi: 10.3892/mco.2017.1195. Epub 2017 Mar 15. PMID: 28515924; PMCID: PMC5431311.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2017 May;6(5):708-712. doi: 10.3892/mco.2017.1195. Epub 2017 Mar 15.

Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer.

Molecular and clinical oncology

Murat Yigit, Serkan Değirmencioğlu, Erhan Ugurlu, Arzu Yaren

Affiliations

  1. Department of Internal Medicine, Pamukkale University, Affiliated to Pamukkale University Hospital, Bagbasi, Denizli 20070, Turkey.
  2. Fahri Goksin Oncology Center, Pamukkale University, Affiliated to Pamukkale University Hospital, Bagbasi, Denizli 20070, Turkey.
  3. Department of Thoracic Oncology, Pamukkale University, Affiliated to Pamukkale University Hospital, Bagbasi, Denizli 20070, Turkey.

PMID: 28515924 PMCID: PMC5431311 DOI: 10.3892/mco.2017.1195

Abstract

Due to poor prognosis in advanced non-small cell lung cancer (NSCLC), new effective markers are required in the monitoring of the disease. The present study aimed to investigate the association between the serum IL-1 receptor antagonist (IL-1Ra) level, overall survival (OS), and treatment response in NSCLC, and to evaluate the usefulness of the serum IL-1Ra level as a prognostic marker for NSCLC. Eighty patients (72 men and 8 women) and 40 healthy volunteers (13 men and 27 women) were included in the present study. The median progression-free survival was 16 weeks for patients with high serum IL-1Ra levels, and 35 weeks for patients with low serum IL-1Ra levels (P=0.027). The median OS was 38 weeks in patients with a high serum IL-1Ra level, and 62 weeks in patients with a low serum IL-1Ra level (P=0.065). The results of the present study have demonstrated that there was a significant correlation between IL-1Ra levels and NSCLC progression and survival, although the correlation between IL-1Ra levels and the response to treatment was not statistically significant. Therefore, the pre-treatment IL-1Ra level has been identified as a putative prognostic factor for NSCLC.

Keywords: non-small cell lung cancer; overall survival; serum interleukin-1 receptor antagonist level; treatment response

References

  1. J Thorac Oncol. 2015 May;10(5):768-77 - PubMed
  2. Adv Exp Med Biol. 2007;601:265-70 - PubMed
  3. Clin Chem Lab Med. 2006;44(9):1092-7 - PubMed
  4. Eur J Haematol. 1996 Jul;57(1):87-95 - PubMed
  5. Am J Pathol. 1993 Sep;143(3):794-803 - PubMed
  6. Lancet Oncol. 2009 May;10(5):453-4 - PubMed
  7. Lung Cancer. 2005 Dec;50(3):285-90 - PubMed
  8. Blood. 1996 Mar 15;87(6):2095-147 - PubMed
  9. Br J Cancer. 2004 Dec 13;91(12):1993-5 - PubMed
  10. Eur J Immunol. 1998 Aug;28(8):2598-602 - PubMed
  11. Blood. 1991 Apr 15;77(8):1627-52 - PubMed
  12. Semin Cancer Biol. 2002 Aug;12(4):277-90 - PubMed
  13. Oncology. 2005;68(2-3):138-45 - PubMed
  14. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  15. Cancer Lett. 2006 May 18;236(2):269-75 - PubMed
  16. Nutr Cancer. 1999;35(2):106-10 - PubMed
  17. J Natl Cancer Inst. 2013 Dec 18;105(24):1871-80 - PubMed
  18. Clin Exp Immunol. 1995 Feb;99(2):303-10 - PubMed
  19. Blood. 1997 Aug 15;90(4):1649-55 - PubMed
  20. Am J Respir Cell Mol Biol. 2012 Jul;47(1):67-79 - PubMed
  21. J Transl Med. 2006 Nov 10;4:48 - PubMed
  22. J Thorac Oncol. 2016 Aug;11(8):1311-8 - PubMed

Publication Types